Search

Your search keyword '"Janaszak-Jasiecka, Anna"' showing total 22 results
Start Over Author "Janaszak-Jasiecka, Anna" Publication Year Range Last 50 years
22 results on '"Janaszak-Jasiecka, Anna"'

8. Pathogenesis of psoriasis in the 'omic' era. Part III. Metabolic disorders, metabolomics, nutrigenomics in psoriasis

Author

Owczarczyk-Saczonek, Agnieszka, Purzycka-Bohdan, Dorota, Nedoszytko, Bogusław, Reich, Adam, Szczerkowska-Dobosz, Aneta, Bartosiñska, Joanna, Batycka-Baran, Aleksandra, Czajkowski, Rafał, Dobrucki, Iwona T., Dobrucki, Lawrence W., Górecka-Sokołowska, Magdalena, Janaszak-Jasiecka, Anna, Kalinowski, Leszek, Krasowska, Dorota, Radulska, Adrianna, Reszka, Edyta, Samotij, Dominik, Słominski, Andrzej, Słominski, Radomir, Sobalska-Kwapis, Marta, Stawczyk-Macieja, Marta, Strapagiel, Dominik, Szczêch, Justyna, Żmijewski, Michał, and Nowicki, Roman J.

Subjects
Review Paper, inflammation, proteomic nutrigenomics, psoriasis, metabolomics, metabolic syndrome
Abstract

Psoriasis is a systemic disease that is strictly connected with metabolic disorders (insulin resistance, atherogenic dyslipidemia, arterial hypertension, and cardiovascular diseases). It occurs more often in patients with a more severe course of the disease. Obesity is specially an independent risk factor and it is associated with a worse treatment outcome because of the high inflammatory activity of visceral fatty tissue and the production of inflammatory mediators involved in the development of both psoriasis and metabolic disorders. However, in psoriasis the activation of the Th17/IL-17 and the abnormalities in the Th17/Treg balance axis are observed, but this pathomechanism does not fully explain the frequent occurrence of metabolic disorders. Therefore, there is a need to look for better biomarkers in the diagnosis, prognosis and monitoring of concomitant disorders and therapeutic effects in psoriasis. In addition, the education on the use of a proper diet as a prophylaxis for the development of the above disorders is an important element of holistic care for a patient with psoriasis. Diet may affect gene expression due to epigenetic modification which encompasses interactions of environment, nutrition and diseases. Patients with psoriasis should be advised to adopt proper diet and dietician support.

Published
2020

9. Concurrent DNA Copy-Number Alterations and Mutations in Genes Related to Maintenance of Genome Stability in Uninvolved Mammary Glandular Tissue from Breast Cancer Patients

Author

Ronowicz, Anna, Janaszak-Jasiecka, Anna, Skokowski, Jarosław, Madanecki, Piotr, Bartoszewski, Rafal, Bałut, Magdalena, Seroczyńska, Barbara, Kochan, Kinga, Bogdan, Adam, Butkus, Małgorzata, Pęksa, Rafał, Ratajska, Magdalena, Kuźniacka, Alina, Wasag, Bartosz, Gucwa, Magdalena, Krzyżanowski, Maciej, Jaśkiewicz, Janusz, Jankowski, Zbigniew, Forsberg, Lars, Ochocka, Renata J., Limon, Janusz, Crowley, Michael R., Buckley, Patrick G., Messiaen, Ludwine, Dumanski, Jan P., and Piotrowski, Arkadiusz

Published
2015
Full Text
View/download PDF

11. Genome‐wide mRNA profiling identifies RCAN1 and GADD45A as regulators of the transitional switch from survival to apoptosis during ER stress

Author

Bartoszewski, Rafal, primary, Gebert, Magdalena, additional, Janaszak‐Jasiecka, Anna, additional, Cabaj, Aleksandra, additional, Króliczewski, Jarosław, additional, Bartoszewska, Sylwia, additional, Sobolewska, Aleksandra, additional, Crossman, David K., additional, Ochocka, Renata, additional, Kamysz, Wojciech, additional, Kalinowski, Leszek, additional, Dąbrowski, Michał, additional, and Collawn, James F., additional

Published
2020
Full Text
View/download PDF

12. Pathogenesis of psoriasis in the “omic” era. Part II. Genetic, genomic and epigenetic changes in psoriasis

Author

Nedoszytko, Bogusław, primary, Szczerkowska-Dobosz, Aneta, additional, Stawczyk-Macieja, Marta, additional, Owczarczyk-Saczonek, Agnieszka, additional, Reich, Adam, additional, Bartosińska, Joanna, additional, Batycka-Baran, Aleksandra, additional, Czajkowski, Rafał, additional, Dobrucki, Iwona, additional, Dobrucki, Lawrence, additional, Górecka-Sokołowska, Magdalena, additional, Janaszak-Jasiecka, Anna, additional, Kalinowski, Leszek, additional, Krasowska, Dorota, additional, Purzycka-Bohdan, Dorota, additional, Radulska, Adrianna, additional, Reszka, Edyta, additional, Samotij, Dominik, additional, Sobalska-Kwapis, Marta, additional, Słominski, Andrzej, additional, Słominski, Radomir, additional, Strapagiel, Dominik, additional, Szczęch, Justyna, additional, Żmijewski, Michał, additional, and Nowicki, Roman, additional

Published
2020
Full Text
View/download PDF

13. Pathogenesis of psoriasis in the “omic” era. Part IV. Epidemiology, genetics, immunopathogenesis, clinical manifestation and treatment of psoriatic arthritis

Author

Szczerkowska-Dobosz, Aneta, primary, Krasowska, Dorota, additional, Bartosińska, Joanna, additional, Stawczyk-Macieja, Marta, additional, Walczak, Aleksandra, additional, Owczarczyk-Saczonek, Agnieszka, additional, Reich, Adam, additional, Batycka-Baran, Aleksandra, additional, Czajkowski, Rafał, additional, Dobrucki, Iwona, additional, Dobrucki, Lawrence, additional, Górecka-Sokołowska, Magdalena, additional, Janaszak-Jasiecka, Anna, additional, Kalinowski, Leszek, additional, Nowicki, Roman, additional, Płoska, Agata, additional, Purzycka-Bohdan, Dorota, additional, Radulska, Adrianna, additional, Reszka, Edyta, additional, Samotij, Dominik, additional, Siekierzycka, Anna, additional, Slominski, Andrzej T., additional, Slominski, Radomir M., additional, Sobalska-Kwapis, Marta, additional, Strapagiel, Dominik, additional, Szczęch, Justyna, additional, Żmijewski, Michał, additional, and Nedoszytko, Bogusław, additional

Published
2020
Full Text
View/download PDF

20. Pathogenesis of psoriasis in the "omic" era. Part IV. Epidemiology, genetics, immunopathogenesis, clinical manifestation and treatment of psoriatic arthritis.

Author

Szczerkowska-Dobosz A, Krasowska D, Bartosińska J, Stawczyk-Macieja M, Walczak A, Owczarczyk-Saczonek A, Reich A, Batycka-Baran A, Czajkowski R, Dobrucki IT, Dobrucki LW, Górecka-Sokołowska M, Janaszak-Jasiecka A, Kalinowski L, Nowicki RJ, Płoska A, Purzycka-Bohdan D, Radulska A, Reszka E, Samotij D, Siekierzycka A, Slominski AT, Slominski RM, Sobalska-Kwapis M, Strapagiel D, Szczęch J, Żmijewski MA, and Nedoszytko B

Abstract

Psoriatic arthritis (PsA) is a chronic, progressive, inflammatory arthropathy associated with psoriasis as well as a complex pathogenesis. Genetic and environmental factors trigger the development of the immune-mediated auto-inflammatory response in different sites: skin, bone marrow, entheses and synovial tissues. Studies of the last two decades have changed the view of PsA from a mild, non-progressive arthritis to an inflammatory systemic disease with serious health consequences, not only associated with joint dysfunction, but also with an increased risk of cardiovascular disease and socioeconomic consequences with significantly reduced quality of life. The joint damage starts early in the course of the disease, thus early recognition and treatment with modern biological treatments, which may modify the natural history and slow down progression of this debilitating disease, is essential for the patient long-term outcome., Competing Interests: The authors declare no conflict of interest., (Copyright © 2020 Termedia.)

Published
2020
Full Text
View/download PDF

21. Pathogenesis of psoriasis in the "omic" era. Part III. Metabolic disorders, metabolomics, nutrigenomics in psoriasis.

Author

Owczarczyk-Saczonek A, Purzycka-Bohdan D, Nedoszytko B, Reich A, Szczerkowska-Dobosz A, Bartosiñska J, Batycka-Baran A, Czajkowski R, Dobrucki IT, Dobrucki LW, Górecka-Sokołowska M, Janaszak-Jasiecka A, Kalinowski L, Krasowska D, Radulska A, Reszka E, Samotij D, Słominski A, Słominski R, Sobalska-Kwapis M, Stawczyk-Macieja M, Strapagiel D, Szczêch J, Żmijewski M, and Nowicki RJ

Abstract

Psoriasis is a systemic disease that is strictly connected with metabolic disorders (insulin resistance, atherogenic dyslipidemia, arterial hypertension, and cardiovascular diseases). It occurs more often in patients with a more severe course of the disease. Obesity is specially an independent risk factor and it is associated with a worse treatment outcome because of the high inflammatory activity of visceral fatty tissue and the production of inflammatory mediators involved in the development of both psoriasis and metabolic disorders. However, in psoriasis the activation of the Th17/IL-17 and the abnormalities in the Th17/Treg balance axis are observed, but this pathomechanism does not fully explain the frequent occurrence of metabolic disorders. Therefore, there is a need to look for better biomarkers in the diagnosis, prognosis and monitoring of concomitant disorders and therapeutic effects in psoriasis. In addition, the education on the use of a proper diet as a prophylaxis for the development of the above disorders is an important element of holistic care for a patient with psoriasis. Diet may affect gene expression due to epigenetic modification which encompasses interactions of environment, nutrition and diseases. Patients with psoriasis should be advised to adopt proper diet and dietician support., Competing Interests: The authors declare no conflict of interest., (Copyright: © 2020 Termedia Sp. z o. o.)

Published
2020
Full Text
View/download PDF

22. Pathogenesis of psoriasis in the "omic" era. Part II. Genetic, genomic and epigenetic changes in psoriasis.

Author

Nedoszytko B, Szczerkowska-Dobosz A, Stawczyk-Macieja M, Owczarczyk-Saczonek A, Reich A, Bartosiñska J, Batycka-Baran A, Czajkowski R, Dobrucki IT, Dobrucki LW, Górecka-Sokołowska M, Janaszak-Jasiecka A, Kalinowski L, Krasowska D, Purzycka-Bohdan D, Radulska A, Reszka E, Samotij D, Sobalska-Kwapis M, Słominski A, Słominski R, Strapagiel D, Szczêch J, Żmijewski M, and Nowicki RJ

Abstract

Psoriasis is a multifactorial disease in which genetic, environmental and epigenetic factors regulating gene expression play a key role. In the "genomic era", genome-wide association studies together with target genotyping platforms performed in different ethnic populations have found more than 50 genetic susceptible markers associated with the risk of psoriasis which have been identified so far. Up till now, the strongest association with the risk of the disease has been proved for HLA-C*06 gene. The majority of other psoriasis risk SNPs are situated near the genes encoding molecules involved in adaptive and innate immunity, and skin barrier function. Many contemporary studies indicate that the epigenetic changes: histone modification, promoter methylations, long non-coding and micro-RNA hyperexpression are considered as factors contributing to psoriasis pathogenesis as they regulate abnormal keratinocyte differentiation and proliferation, aberrant keratinocytes - inflammatory cells communication, neoangiogenesis and chronic inflammation. The circulating miRNAs detected in the blood may become specific markers in the diagnosis, prognosis and response to the treatment of the disease. The inhibition of expression in selected miRNAs may be a new promising therapy option for patients with psoriasis., Competing Interests: The authors declare no conflict of interest., (Copyright: © 2020 Termedia Sp. z o. o.)

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results